Mike gained a 1st Class BSc in Biochemistry from Kings College London (with a 1-year work placement at Smith, Kline & French Ltd., during which he published his first research paper). After his PhD from the University of Liverpool (as a Glaxo Research Studentship) on breast cancer metastasis, he secured further funding from Glaxo Inc. for a subsequent post-doc.
The majority of his career as a researcher has been in the field of translational cancer research, primarily breast cancer and lung cancer. He spent 11 years working for Clatterbridge Cancer Research Trust, a small independent research charity associated with Clatterbridge Centre for Oncology. In 2007 he returned to the University of Liverpool and in 2011, secured his current position in the Roy Castle Lung Cancer Research Programme with Prof John Field and Dr Lakis Liloglou.
Having participated in the EU FP7 CURELUNG & LCAOS research projects, he currently heads the Clinical Resources group and manages the Liverpool Lung Project biobank and data-repository. His research also includes: risk modelling for lung cancer; analysis of the UKLS lung cancer screening trial; the NIH-funded Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) project; and collaborative projects as part of the International Lung Cancer Consortium (ILCCO).
His main areas of research focus are discovery and validation of clinically-relevant biomarkers, precision public health and low-dose CT lung cancer screening.